GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ARE LEADERS IN REDUCING CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Developed in the last 15 years, a new class of sugar-lowering drugs - glucagon-like peptide-1 receptor agonists - has become one of the leaders in the treatment of type 2 diabetes mellitus, prediabetes and obesity. Numerous studies have proven the cardiovascular safety of this medicine class, their cardioprotective and nephroprotective effects. That served as the basis for making changes to clinical recommendations on the management of patients with type 2 diabetes mellitus.